Apollomics, Inc. (NASDAQ:APLM) Short Interest Down 98.3% in November

Apollomics, Inc. (NASDAQ:APLM) was the target of a large decrease in short interest during the month of November. As of November 15th, there was short interest totalling 2,900 shares, a decrease of 98.3% from the October 31st total of 168,500 shares. Based on an average daily volume of 283,800 shares, the short-interest ratio is presently 0.0 days.

Apollomics Price Performance

Shares of APLM traded up $0.74 during mid-day trading on Friday, hitting $8.90. 181,869 shares of the company’s stock traded hands, compared to its average volume of 92,959. The business’s 50-day moving average price is $12.84 and its 200-day moving average price is $17.35. Apollomics has a 1 year low of $7.55 and a 1 year high of $108.00.

Institutional Investors Weigh In On Apollomics

A hedge fund recently raised its stake in Apollomics stock. George Kaiser Family Foundation lifted its stake in Apollomics, Inc. (NASDAQ:APLM) by 2,585.6% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 670,976 shares of the company’s stock after purchasing an additional 645,992 shares during the quarter. Apollomics comprises approximately 0.0% of George Kaiser Family Foundation’s holdings, making the stock its 18th largest position. George Kaiser Family Foundation owned 0.75% of Apollomics worth $141,000 as of its most recent SEC filing. Institutional investors own 19.13% of the company’s stock.

Apollomics Company Profile

Apollomics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company’s products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain.